Breast Cancer Clinical Trial
Official title:
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Verified date | August 2023 |
Source | Elevation Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
Status | Active, not recruiting |
Enrollment | 75 |
Est. completion date | March 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: To be eligible for participation in the study, patients must meet the following inclusion criteria: - Locally-advanced or metastatic solid tumor with an NRG1 gene fusion identified through molecular assays, such as PCR, NGS (RNA or DNA) or FISH, by a CLIA-certified or similarly accredited laboratory - Availability of fresh or archived FFPE tumor sample to be submitted to a central laboratory for confirmation of NRG1 gene fusion status - Patients should have received a minimum of one prior standard therapy appropriate for their tumor type and stage of disease, progressed or been nonresponsive to these available therapies, with no further available curative therapy options - = 18 years of age - ECOG performance status (PS) 0, 1 or 2 - Patients must have at least one measurable extra-cranial lesion as defined by RECIST v1.1 - Adequate hepatic function defined as: - Serum AST and serum ALT < 2.5 × upper limit of normal (ULN), or AST and ALT < 5 × ULN if liver function abnormalities due to underlying malignancy - Total bilirubin < 2.0 ULN. Subjects with a known history of Gilberts Disease and an isolated elevation of indirect bilirubin are eligible - Adequate hematologic status, defined as: - Absolute neutrophil count (ANC) =1.5 × 109/L not requiring growth factor support for at least 7 days prior to Screening, and - Platelet count =100.0×109/L not requiring transfusion support for at least 7 days prior to Screening - Able to provide informed consent or have a legal representative able and willing to do so - Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation - Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following study completion; this may include barrier methods such as condom or diaphragm with spermicidal gel. Exclusion Criteria: - Known, actionable oncogenic driver mutation other than NRG1 fusion where available standard therapy is indicated - Life expectancy < 3 months - Pregnant or lactating - Prior treatment with ERBB3/HER3 directed therapy (Cohort 1 only) - Prior treatment with pan-ERBB or any ERBB/HER2/HER3 directed therapy (Cohort 1 only) - Symptomatic or untreated brain metastases (Note: Patients with asymptomatic brain metastases treated with radiation or surgery and without evidence of progression by imaging at screening are eligible to participate in the study. Patients requiring ongoing corticosteroids to treat brain metastases will not be eligible). - Received other investigational agent or anticancer therapy within 28 days prior to planned start of seribantumab or 5 half-lives, whichever is shorter - Prior to initiation of seribantumab treatment, patients must have recovered from clinically significant toxicities from prior anticancer or investigational therapy - Any other active malignancy requiring systemic therapy - Known hypersensitivity to any of the components of seribantumab or previous CTCAE grade 3 or higher hypersensitivity reactions to fully human monoclonal antibodies - Clinically significant cardiac disease, including symptomatic congestive heart failure, unstable angina, acute myocardial infarction within 12 months of planned first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de pointes) - Active uncontrolled systemic bacterial, viral, or fungal infection - Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Hobart Hospital | Hobart | Tasmania |
Australia | Peter MacCallum Cancer Centre | Melbourne | Victoria |
Australia | Linear Clinical Research Ltd. | Nedlands | Western Australia |
Australia | St. Vincent's Hospital | Sydney | New South Wales |
Canada | William Osler Health System | Brampton | Ontario |
Canada | BC Cancer | Vancouver | British Columbia |
Korea, Republic of | Seoul National University Hospital | Seoul | |
United States | ThedaCare Regional Cancer Center | Appleton | Wisconsin |
United States | University Cancer And Blood Center | Athens | Georgia |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Oncology & Hematology Associates of Southwest Virginia Inc., DBA Blue Ridge Cancer Care | Blacksburg | Virginia |
United States | Massachusetts General Hospital Cancer Center | Boston | Massachusetts |
United States | Montefiore Medical Center | Bronx | New York |
United States | Levine Cancer Institute | Charlotte | North Carolina |
United States | Northwestern University | Chicago | Illinois |
United States | The Ohio State University | Columbus | Ohio |
United States | Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas |
United States | University of Colorado Denver | Denver | Colorado |
United States | Henry Ford | Detroit | Michigan |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | Compassionate Care Research Group Inc. | Fountain Valley | California |
United States | Penn State Health Hershey Medical Center Cancer Institute | Hershey | Pennsylvania |
United States | Hawaii Cancer Care | Honolulu | Hawaii |
United States | The University of Texas M.D. Anderson Cancer Center | Houston | Texas |
United States | Pacific Shores Medical Group | Huntington Beach | California |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | University of Wisconsin | Madison | Wisconsin |
United States | Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Medical Oncology Hematology Consultants | Newark | Delaware |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | University of California - Irvine Medical Center | Orange | California |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Metro Minnesota CCOP | Saint Louis Park | Minnesota |
United States | Utah Cancer Specialists | Salt Lake City | Utah |
United States | HonorHealth | Scottsdale | Arizona |
United States | Sanford Oncology Clinic | Sioux Falls | South Dakota |
United States | Northwest Medical Specialties, PLLC | Tacoma | Washington |
United States | Moffitt Cancer Center | Tampa | Florida |
United States | Georgetown University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Elevation Oncology |
United States, Australia, Canada, Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | The primary objective of this study is to determine the overall objective response rate (ORR) by independent radiologic review to single agent seribantumab in patients with NRG1 gene fusion positive advanced cancer according to RECIST 1.1 | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |